Asahi Intecc Co., Ltd.
Regarding the Conclusion of an Exclusive Sales Agreement in the Japanese Market for Embolic Agents
Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan for the embolic agent "Nexsphere-F™" from Korea's NEXTBIOMEDICAL on April 9, 2026. The contract period is five years following insurance listing, with no impact on consolidated results for the current fiscal year.
Key Figures
- Contract Signing Date: 2026年4月9日
- Contract Period: Five years after insurance listing (assumed annual renewal)
- Impact on Current Consolidated Results: None
AI要約
Contract Overview
Asahi Intecc Co., Ltd. concluded an exclusive sales agreement in Japan on April 9, 2026, for the embolic agent "Nexsphere-F™" developed and manufactured by Korea's NEXTBIOMEDICAL CO., LTD. Although the product is not yet approved by regulatory authorities, the company aims for insurance listing after obtaining regulatory approval and plans to start direct sales to hospitals through consolidated subsidiaries. The contract period is five years following insurance listing, with expectations for annual renewal thereafter.
Future Outlook and Impact
"Nexsphere-F™" is already marketed in direct sales regions in Europe and is used in TAME treatments. Leveraging its relationships with physicians and sales network, Asahi Intecc anticipates the spread of this product and synergies with related products. There is no impact expected on the consolidated results for the current fiscal year from this contract. The company aims to contribute to improving the quality of life for chronic pain patients by offering new treatment options.
